Therapeutic Approaches for PDAC Harboring BRCA Mutations and HRD

Download this slideset to review the latest therapeutic approaches for patients with pancreatic cancer harboring BRCA mutations.
person default
Dirk Arnold, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.93 MB
Released: January 21, 2021

Acknowledgements

Supported by an educational grant from
AstraZeneca

Related Content

In this short slideset from Clinical Care Options (CCO), experts review second-line treatment options for advanced pancreatic cancer

Andrew H. Ko, MD Released: February 19, 2021

Video of expert discussion of second-line therapy for metastatic pancreatic cancer from Clinical Care Options (CCO)

Andrew H. Ko, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 19, 2021 Expired: February 18, 2022

In this short slideset from Clinical Care Options (CCO), experts review first-line treatment options for advanced pancreatic cancer

Andrew H. Ko, MD Released: February 17, 2021

Video of expert discussion of first-line therapy for metastatic pancreatic cancer from Clinical Care Options (CCO)

Andrew H. Ko, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 17, 2021 Expired: February 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue